Navigation Links
FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
Date:9/19/2011

women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.  In these patients with prostate cancer, Prolia reduced the incidence of vertebral fractures.

Prolia is approved in the European Union (EU) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

Prolia is approved in the U.S., Canada, Australia, and in all 27 EU member states as well as in Norway, Iceland and Liechtenstein. Applications in the rest of the world are pending.

Prolia is administered as a single subcutaneous injection of 60 mg once every six months. For further information on Prolia, including prescribing information and medication guide, please visit: www.prolia.com.  

Important U.S. Safety Information

Prolia is contraindicated in patients with hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating Prolia. Hypocalcemia may worsen, especially in patients with severe renal impairment. All patients should be adequately supplemented with calcium and vitamin D. Patients receiving Prolia should not receive XGEVA®, as both Prolia and XGEVA contain the same active ingredient, denosumab.

In the Phase 3 pivotal study of women with postmenopausal osteoporosis (n=7808), serious infections leading to hospitalizations were reported more frequently in the Prolia-treated patient group.
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013  Grifols, a global healthcare company based ... from a study demonstrating that a higher dose of ... levels of the alpha 1 protein in patients ... are considered within the normal range for healthy individuals. ... low levels of the alpha 1 proteinase inhibitor ...
(Date:5/22/2013)...  BD (Becton, Dickinson and Company) (NYSE: ... today the publication of its 2012 Sustainability Report ... continues to focus on the Company,s shared value approach ... of shared value — creating value for shareholders by ... are fundamental to our strategy," said Vincent ...
(Date:5/22/2013)... Calif. , May 22, 2013 Rigel ... the clinical advancement of three programs in development. The ... a JAK/SYK inhibitor, R348, being developed by Rigel as ... programs are aimed at oncology targets and are being ... under development by BerGenBio AS (BerGenBio) and a ligase ...
Breaking Medicine Technology:Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 2Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 4
... PTC Therapeutics, Inc. (PTC) today announced the appointment of ...  Dr. Spiegel served previously as Chief Medical Officer of ... Barth, M.D. to Vice President of Clinical Development.   ... report to Stuart W. Peltz, Ph.D., President and CEO ...
... -- Winner Medical Group Inc. (Nasdaq: ... medical dressings, medical disposables and non-woven fabric made ... announced that Mr. Jianquan Li, Winner Medical,s founder, ... the Distinguished Contribution award for 2010 by the ...
Cached Medicine Technology:PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 2PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 3Winner Medical CEO Awarded and Appointed Position by CNITA 2Winner Medical CEO Awarded and Appointed Position by CNITA 3Winner Medical CEO Awarded and Appointed Position by CNITA 4
(Date:5/22/2013)... WEDNESDAY, May 22 (HealthDay News) -- Roughly four in ... obstructive pulmonary disease (COPD) actually do not have the ... issue: Faulty diagnoses were made based on an evaluation ... "gold standard" disease test known as spirometry, which shows ... the amount of air they can exhale and how ...
(Date:5/22/2013)... New research from Brigham and Women,s Hospital (BWH) finds ... uncommon but deadly lung disease, may be effective in ... findings will be presented at the American Thoracic Society ... New England Journal of Medicine on May 22 ... edition., "While this variant of the MUC5B gene is ...
(Date:5/22/2013)... ATS 2013, PHILADELPHIA ─More than 40 percent of ... funded clinic did not have the disease, researchers ... diagnostic "gold standard" for chronic obstructive pulmonary disease. ... the under-diagnosis of COPD, there has not been ... of over-diagnosis," said Christian Ghattas, MD., MSc, ...
(Date:5/22/2013)... In the past decade, more ... courts with donated uniforms, shoes, balls and other ... to partnering with manufacturers to provide youth with sporting ... $8.8 million in sports and fitness equipment over 10 ... outfitted for physical activity. , An inaugural donation ...
(Date:5/22/2013)... Alabama (PRWEB) May 22, 2013 ... solutions to state Health and Human Services and ... of Mental Health (ADMH) selected the CoCENTRIX ... platform to manage the Health Records and coordinate ... psychiatric hospitals. , CoCENTRIX is transitioning the ...
Breaking Medicine News(10 mins):Health News:COPD May Be Over-Diagnosed Among Uninsured 2Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:Study finds COPD is over-diagnosed among uninsured patients 2Health News:Study finds COPD is over-diagnosed among uninsured patients 3Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3
... salon to help San Diego,s frantic families rid themselves of lice ... the head lice helpers, ( www.hairfairies.com ) today announced that it ... San Diego on May 12, 2009. , , ... salon dedicated to removing head lice. With salons in New ...
... May 12 Blue Cross and Blue Shield of ... an accreditation status of "Excellent" for its HMO products ... is an independent, non-profit organization that evaluates how well ... system -- physicians, hospitals, other providers and administrative services ...
... Manage Their Daily and Weekly MedicationsLAWRENCE, Mass., May 12 ... healthcare industry as a whole, it,s individual healthcare professionals ... a smaller scale.Goss, a medical technologist, enjoys her line ... good about what I do in the hospital lab," ...
... N.H., May 12 After very successful test marketing ... has begun selling its all-natural sports mints called Muscle ... and several electrolytes in a chewable mint, it is ... ingredients are used, and this is reflected in its ...
... PhD, FNP Join Together to Raise Awareness of Common, ... Fibromyalgia is often called an "invisible" illness because ... sick. However, something as simple as a hug ... fibromyalgia is one of the most common chronic, widespread ...
... Evidence-based, Unbiased Determinations Use Latest Clinical InformationLANSDALE, Penn., ... today equals 17 percent of the U.S. gross ... will equal 20 percent. Most politicians and healthcare ... inefficiencies, inflated prices, poor management and waste that ...
Cached Medicine News:Health News:Lice Removal Salon Offers San Diego an Upscale Solution to an Undesirable Problem 2Health News:NCQA Accreditation Status of Excellence Awarded to Blue Cross and Blue Shield of Georgia 2Health News:Healthcare Professional Is Working to Make a Difference, One Dose at a Time 2Health News:New Class of Sports Nutrition Product Launched 2Health News:VIDEO from Medialink, the National Fibromyalgia Association and Pfizer: The Painful Truth about Fibromyalgia 2Health News:IROs Help Cut Health Plan Costs During the Recession 2
... the serum tube is specially coated with ... coagulation process. Serum / gel tubes contain ... the tube; during centrifugation, this gel forms ... the blood cells. In the primary tube ...
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
Medicine Products: